1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Activity of novel lipid glycine transporter inhibitors on synaptic signalling in the dorsal horn of the spinal cord

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background and Purpose

          Inhibitory neurotransmission plays an important role in controlling excitability within nociceptive circuits of the spinal cord dorsal horn. Loss of inhibitory signalling is thought to contribute to the development of pathological pain. Preclinical studies suggest that increasing inhibitory glycinergic signalling is a good therapeutic strategy for treating pain. One approach to increase synaptic glycine is to inhibit the activity of the glycine transporter 2 (GlyT2) on inhibitory nerve terminals. These transporters are involved in regulating glycine concentrations and recycling glycine into presynaptic terminals. Inhibiting activity of GlyT2 increases synaptic glycine, which decreases excitability in nociceptive circuits and provides analgesia in neuropathic and inflammatory pain models.

          Experimental Approach

          We investigated the effects of reversible and irreversible GlyT2 inhibitors on inhibitory glycinergic and NMDA receptor‐mediated excitatory neurotransmission in the rat dorsal horn. The effect of these drugs on synaptic signalling was determined using patch‐clamp electrophysiology techniques to measure glycine‐ and NMDA‐mediated postsynaptic currents in spinal cord slices in vitro.

          Key Results

          We compared activity of four compounds that increase glycinergic tone with a corresponding increase in evoked glycinergic postsynaptic currents. These compounds did not deplete synaptic glycine release over time. Interestingly, none of these compounds increased glycine‐mediated excitatory signalling through NMDA receptors. The results suggest that these compounds preferentially inhibit GlyT2 over G1yT1 with no potentiation of the glycine receptor and without inducing spillover from inhibitory to excitatory synapses.

          Conclusions and Implications

          GlyT2 inhibitors increase inhibitory neurotransmission in the dorsal horn and have potential as pain therapeutics.

          Linked Articles

          This article is part of a themed section on Recent Advances in Targeting Ion Channels to Treat Chronic Pain. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.12/issuetoc

          Related collections

          Author and article information

          Contributors
          wendy.imlach@monash.edu
          Journal
          Br J Pharmacol
          Br. J. Pharmacol
          10.1111/(ISSN)1476-5381
          BPH
          British Journal of Pharmacology
          John Wiley and Sons Inc. (Hoboken )
          0007-1188
          1476-5381
          14 April 2018
          June 2018
          : 175
          : 12 , Themed Section: Recent Advances in Targeting Ion Channels to Treat Chronic Pain. Guest Editors: Edward B Stevens and Gary J Stephens ( doiID: 10.1111/bph.v175.12 )
          : 2337-2347
          Affiliations
          [ 1 ] Pain Management Research Institute, Kolling Institute of Medical Research The University of Sydney, Royal North Shore Hospital St Leonards NSW Australia
          [ 2 ] School of Mathematical and Physical Sciences, Faculty of Science University of Technology Sydney Ultimo NSW Australia
          [ 3 ] Discipline of Pharmacology, Sydney Medical School University of Sydney Sydney NSW Australia
          [ 4 ] Department of Physiology, Monash Biomedicine Discovery Institute Monash University Melbourne VIC Australia
          Author notes
          [*] [* ] Correspondence Wendy L. Imlach, Department of Physiology, Monash Biomedicine Discovery Institute, Monash University, Melbourne, Victoria 3800, Australia. E‐mail: wendy.imlach@ 123456monash.edu
          Author information
          http://orcid.org/0000-0002-7521-9969
          Article
          PMC5980266 PMC5980266 5980266 BPH14189 2017-BJP-0914-RPT-G.R2
          10.1111/bph.14189
          5980266
          29500820
          e3836860-bcb1-401a-9b3e-9a7e9d38a0e3
          © 2018 The British Pharmacological Society
          History
          : 14 July 2017
          : 03 February 2018
          : 06 February 2018
          Page count
          Figures: 6, Tables: 1, Pages: 11, Words: 6844
          Funding
          Funded by: RE Lake Fellowship
          Funded by: National Health and Medical Research Council
          Award ID: APP1125877
          Award ID: APP1139591
          Award ID: APP1082570
          Categories
          Research Paper
          Themed Section: Research Papers
          Custom metadata
          2.0
          bph14189
          June 2018
          Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.4.0 mode:remove_FC converted:31.05.2018

          Comments

          Comment on this article